healthcare price transparency and hsas

Summary#

This bill makes big changes in five main areas: health savings accounts (HSAs), a new “health marketplace pool” option, stronger price-transparency rules for hospitals, labs, imaging centers, and insurers, rules about drug payments and rebates in Medicare, and expanded access to certain prescription drugs through pharmacists and similar providers. It also contains a technical change to Federal Reserve rules.

• HSAs: Removes the rule that HSAs must be paired with high-deductible health plans and expands what counts as qualified HSA spending (including limited healthy food, vitamins, fitness, direct primary care fees, charity contributions, rollovers from FSAs/HRAs, expanded beneficiary rollover rights, and other new transfer rules). It also increases contribution limits by tying them to another tax-code amount and gives HSAs bankruptcy protection like IRAs.
• Health Marketplace for All: Creates a legal category called a “health marketplace pool” that can be treated as an employer for offering group plans or group insurance, including drug-only plans, subject to nondiscrimination rules and other requirements.
• Price transparency: Strengthens and extends federal price-disclosure rules. Hospitals must publish machine-readable and consumer-friendly price lists (including payer-negotiated rates and discounted cash prices) and face daily fines for noncompliance. Similar monthly or annual public reporting rules apply to clinical laboratories, imaging providers, ambulatory surgical centers, and health plans.
• Data access and oversight: Requires that group health plans, plan sponsors, and plan auditors get broad access to claims and contract data from providers, insurers, and third-party administrators. It limits contractual “gag” clauses and creates civil penalties for noncompliance.
• Drugs and expanded access: For certain drugs subject to “maximum fair price” negotiation in Medicare, the bill requires manufacturers to pay rebates when Medicare would otherwise pay more. It also directs HHS to create a list of “expanded-access prescription drugs” that pharmacists, advanced practice nurses, physician assistants, and some others may dispense/administer under federal protocols; states may opt out by law.

What it means for you#

• Patients / Consumers

  • Hospitals, labs, imaging centers, and many providers must publish prices and negotiated rates in machine-readable files and consumer-friendly displays. This could make it easier to see and compare prices before care.
  • Providers must give itemized bills and cannot start collections until they provide required itemization. Emergency and post-service explanations of benefits are expanded.
  • Some wellness items (healthy food, vitamins, fitness) could be paid from HSAs up to monthly limits tied to the HSA balance.
  • Certain prescription drugs may be available directly from pharmacists or other non-physician providers if listed by HHS (unless your state opts out).

• People who use HSAs

  • HSAs could be used without being enrolled in a high-deductible plan. More types of payments and rollovers are allowed, and contribution limits are increased by linking them to another tax-code amount.
  • HSAs receive bankruptcy protection like IRAs.
  • Employers offering at least $450/month HSA contributions may be treated as meeting the employer mandate for offering minimum coverage for that month.

• Employers, plan sponsors, and insurers

  • Health marketplace pools may offer group plans and be treated as employers for offering coverage, including drug-only plans.
  • Contracts with administrators, networks, and providers must not block plan access to claims, payment, contract, and audit data. Plans can require broad disclosures and audits.
  • Health plans must publish three machine-readable files monthly with in-network rates, historical net prices for drugs, and out-of-network billed/allowed amounts for recent periods.
  • Noncompliance with transparency or data-access rules can lead to civil monetary penalties; amounts and enforcement mechanisms are specified in the bill.

• Hospitals, labs, imaging centers, ambulatory surgical centers, and ASCs

  • Must prepare and publish detailed price lists (gross charge, discounted cash price, payer-specific negotiated charges, max/min negotiated amounts, billing codes) under a format set by HHS. Deadlines in law include formats by Jan 1, 2027 or 2028 depending on provider type.
  • Face monitoring, required senior attestation of accuracy, and staged civil monetary penalties for failure to comply.

• Drug manufacturers and Medicare

  • For selected drugs with a negotiated maximum fair price, manufacturers must remit rebates to Medicare in some quarters where higher payments would otherwise apply; beneficiary coinsurance is adjusted to the negotiated-price-based amount.

• Pharmacies and other clinicians

  • HHS will create a list of drugs eligible for “expanded access” dispensing and protocols to allow pharmacists and other specified clinicians to assess, dispense, and administer those drugs, unless a State enacts a law to opt out.

Expenses#

No publicly available information.

• The bill does not include a fiscal note in the provided text.
• This could mean additional administrative costs for hospitals, laboratories, ambulatory surgical centers, insurers, third-party administrators, and government agencies to prepare, publish, audit, and enforce the required machine-readable files and consumer tools.
• The manufacturer rebate provisions could increase receipts to the Medicare SMI trust fund, while potentially changing Medicare and beneficiary payments for affected drugs.
• Large civil penalties and new enforcement tasks could require more staff or resources at HHS and related agencies to monitor and enforce compliance.

Proponents' View#

(The following describes reasons the bill appears intended to achieve, based on the bill text.)

• The bill appears intended to broaden and modernize HSAs so more people can save tax-preferred dollars for health costs and use them for a wider set of health and wellness expenses.
• It appears intended to increase price transparency so consumers can compare costs and to reduce surprise or unclear billing by requiring itemized bills and explanations of benefits.
• The bill appears intended to give group health plans more access to data so plan sponsors can audit payments, detect overpayments, and better manage costs.
• For Medicare drugs subject to negotiated maximum prices, the bill appears intended to require manufacturers to rebate differences to Medicare and to limit beneficiary coinsurance to the negotiated-price-based amount.
• Allowing certain prescription drugs to be dispensed by pharmacists and other clinicians appears intended to expand access and convenience for common or low-risk treatments.

Opponents' View#

(The following are reasonable concerns or criticisms that follow from the bill text or missing details.)

• One concern is that removing the requirement that HSAs be paired with high-deductible health plans could change how HSAs are used and reduce the link between HSAs and cost-sharing incentives; the bill does not clearly explain how this will affect insurance design or risk pooling.
• The bill requires extensive new reporting, machine-readable files, and audits. This could create significant administrative and compliance costs for hospitals, labs, insurers, third-party administrators, and government, and the bill does not provide cost estimates or transition funding.
• The requirement for hospitals and other providers to disclose detailed payer-specific negotiated rates and contract algorithms may be technically and legally complex. The bill delegates much detail to the Secretary, and it is unclear how proprietary contract terms will be handled in practice.
• The bill creates large daily civil penalties in several places. It is unclear how enforcement resources will be scaled and whether smaller providers could face disproportionate burdens.
• Some provisions (for example, transfers and rollovers to a “Trump account” as referenced) rely on definitions outside this text; it is unclear from this bill alone what those accounts are or how they will operate.
• The expanded-access drug pathway is broad but allows States to opt out; the interaction between federal protocols and varying State licensure and scope-of-practice rules could be legally and operationally unclear.